Epigenetic mechanisms in diabetic complications and metabolic memory

Diabetologia

Volumn 58, Issue 3, 2015, Pages 443-455

  Reddy, Marpadga A ^a   Zhang, Erli ^a,b   Natarajan, Rama ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b FUWAI HOSPITAL   (China)

Author keywords

Diabetic complications; DNA methylation; Epigenetics; Epigenomics; Histone modifications; Metabolic memory; Non coding RNA; Review

Indexed keywords

HISTONE; MICRORNA; UNTRANSLATED RNA;

DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DNA METHYLATION; DNA SEQUENCE; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EPIGENETICS; HUMAN; HYPERGLYCEMIA; METABOLIC MEMORY; METABOLIC PARAMETERS; PRIORITY JOURNAL; RETINA CELL; REVIEW; VASCULAR SMOOTH MUSCLE; GENETIC EPIGENESIS; GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS;

DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; RNA, UNTRANSLATED;

EID: 84925519612     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3462-y     Document Type: Review

References (106)

1. Beckman JA, Creager MA, Libby P (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287:2570–2581
2. Ziyadeh FN, Sharma K (2003) Overview: combating diabetic nephropathy. J Am Soc Nephrol 14:1355–1357
3. Fong DS, Aiello L, Gardner TW et al (2003) Diabetic retinopathy. Diabetes Care 26:226–229
4. Natarajan R, Nadler JL (2004) Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol 24:1542–1548
5. Vincent AM, Calabek B, Roberts L, Feldman EL (2013) Biology of diabetic neuropathy. Handb Clin Neurol 115:591–606
6. Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93:137–188
7. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820
8. Kato M, Natarajan R (2014) Diabetic nephropathy—emerging epigenetic mechanisms. Nat Rev Nephrol 10:517–530
9. Woroniecka KI, Park AS, Mohtat D, Thomas DB, Pullman JM, Susztak K (2011) Transcriptome analysis of human diabetic kidney disease. Diabetes 60:2354–2369
10. Dunham I, Kundaje A, Aldred SF et al (2012) An integrated encyclopedia of DNA elements in the human genome. Nature 489:57–74
11. Human Epigenome Task Force (2008) Moving AHEAD with an international human epigenome project. Nature 454:711–715
12. Kanwar YS, Sun L, Xie P, Liu FY, Chen S (2011) A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 6:395–423
13. Geraldes P, King GL (2010) Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 106:1319–1331
14. Ramasamy R, Yan SF, Schmidt AM (2011) Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci 1243:88–102
15. Reddy MA, Natarajan R (2011) Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res 90:421–429
16. Averill MM, Bornfeldt KE (2009) Lipids versus glucose in inflammation and the pathogenesis of macrovascular disease in diabetes. Curr Diabetes Rep 9:18–25
17. Sanchez AP, Sharma K (2009) Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 11:e13
18. Villeneuve LM, Natarajan R (2010) The role of epigenetics in the pathology of diabetic complications. Am J Physiol Ren Physiol 299:F14–F25
19. Writing Team for the DCCT/EDIC Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569
20. EDIC study (2003) Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290:2159–2167
21. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653
22. Chalmers J, Cooper ME (2008) UKPDS and the legacy effect. N Engl J Med 359:1618–1620
23. Li SL, Reddy MA, Cai Q et al (2006) Enhanced proatherogenic responses in macrophages and vascular smooth muscle cells derived from diabetic db/db mice. Diabetes 55:2611–2619
24. Villeneuve LM, Reddy MA, Lanting LL, Wang M, Meng L, Natarajan R (2008) Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflammatory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci U S A 105:9047–9052
25. Reddy MA, Jin W, Villeneuve L et al (2012) Pro-inflammatory role of microRNA-200 in vascular smooth muscle cells from diabetic mice. Arterioscler Thromb Vasc Biol 32:721–729
26. El-Osta A, Brasacchio D, Yao D et al (2008) Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409–2417
27. Brasacchio D, Okabe J, Tikellis C et al (2009) Hyperglycaemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58:1229–1236
28. Kowluru RA (2003) Effect of reinstitution of good glycaemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52:818–823
29. Zhong Q, Kowluru RA (2013) Epigenetic modification of Sod2 in the development of diabetic retinopathy and in the metabolic memory: role of histone methylation. Invest Ophthalmol Vis Sci 54:244–250
30. Zhong Q, Kowluru RA (2013) Regulation of matrix metalloproteinase-9 by epigenetic modifications and the development of diabetic retinopathy. Diabetes 62:2559–2568
31. Zhong Q, Kowluru RA (2011) Epigenetic changes in mitochondrial superoxide dismutase in the retina and the development of diabetic retinopathy. Diabetes 60:1304–1313
32. Engerman RL, Kern TS (1987) Progression of incipient diabetic retinopathy during good glycaemic control. Diabetes 36:808–812
33. Kowluru RA, Abbas SN, Odenbach S (2004) Reversal of hyperglycaemia and diabetic nephropathy: effect of reinstitution of good metabolic control on oxidative stress in the kidney of diabetic rats. J Diabetes Complications 18:282–288
34. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693–705
35. Jones PA (2012) Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 13:484–492
36. Zhou VW, Goren A, Bernstein BE (2011) Charting histone modifications and the functional organization of mammalian genomes. Nat Rev Genet 12:7–18
37. Portela A, Esteller M (2010) Epigenetic modifications and human disease. Nat Biotechnol 28:1057–1068
38. Baylin SB, Jones PA (2011) A decade of exploring the cancer epigenome—biological and translational implications. Nat Rev Cancer 11:726–734
39. Ling C, Groop L (2009) Epigenetics: a molecular link between environmental factors and type 2 diabetes. Diabetes 58:2718–2725
40. Wang J, Wu Z, Li D et al (2012) Nutrition, epigenetics, and metabolic syndrome. Antioxid Redox Signal 17:282–301
41. Sandholm N, Salem RM, McKnight AJ et al (2012) New susceptibility loci associated with kidney disease in type 1 diabetes. PLoS Genet 8:e1002921
42. Luo J, Zhao L, Chen AY et al (2013) TCF7L2 variation and proliferative diabetic retinopathy. Diabetes 62:2613–2617
43. McKnight AJ, McKay GJ, Maxwell AP (2014) Genetic and epigenetic risk factors for diabetic kidney disease. Adv Chron Kidney Dis 21:287–296
44. Maurano MT, Humbert R, Rynes E et al (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337:1190–1195
45. Chen ZX, Riggs AD (2011) DNA methylation and demethylation in mammals. J Biol Chem 286:18347–18353
46. Jirtle RL, Skinner MK (2007) Environmental epigenomics and disease susceptibility. Nat Rev Genet 8:253–262
47. Simmons R (2011) Epigenetics and maternal nutrition: nature v. nurture. Proc Nutr Soc 70:73–81
48. Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA (2010) Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Gen 3:33–42
49. Sapienza C, Lee J, Powell J et al (2011) DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics Off J DNA Methylation Soc 6:20–28
50. Bechtel W, McGoohan S, Zeisberg EM et al (2010) Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med 16:544–550
51. Hasegawa K, Wakino S, Simic P et al (2013) Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 19:1496–1504
52. Ko YA, Mohtat D, Suzuki M et al (2013) Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol 14:R108
53. Pirola L, Balcerczyk A, Tothill RW et al (2011) Genome-wide analysis distinguishes hyperglycaemia regulated epigenetic signatures of primary vascular cells. Genome Res 21:1601–1615
54. Kim ES, Isoda F, Kurland I, Mobbs CV (2013) Glucose-induced metabolic memory in Schwann cells: prevention by PPAR agonists. Endocrinology 154:3054–3066
55. Jin F, Li Y, Ren B, Natarajan R (2011) Enhancers: multi-dimensional signal integrators. Transcription 2:226–230
56. Klose RJ, Zhang Y (2007) Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol 8:307–318
57. Allis CD, Berger SL, Cote J et al (2007) New nomenclature for chromatin-modifying enzymes. Cell 131:633–636
58. Smith E, Shilatifard A (2010) The chromatin signaling pathway: diverse mechanisms of recruitment of histone-modifying enzymes and varied biological outcomes. Mol Cell 40:689–701
59. Rinn JL, Chang HY (2012) Genome regulation by long noncoding RNAs. Annu Rev Biochem 81:145–166
60. Sassone-Corsi P (2013) Physiology. When metabolism and epigenetics converge. Science 339:148–150
61. Abmayr SM, Workman JL (2012) Holding on through DNA replication: histone modification or modifier? Cell 150:875–877
62. Cedar H, Bergman Y (2009) Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 10:295–304
63. Guttman M, Rinn JL (2012) Modular regulatory principles of large non-coding RNAs. Nature 482:339–346
64. Das F, Ghosh-Choudhury N, Venkatesan B, Li X, Mahimainathan L, Choudhury GG (2008) Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta-induced expression of plasminogen activator inhibitor-1. J Cell Physiol 214:513–527
65. Yuan H, Reddy MA, Sun G et al (2013) Involvement of p300/CBP and epigenetic histone acetylation in TGF-beta1-mediated gene transcription in mesangial cells. Am J Physiol Ren Physiol 304:F601–F613
66. Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R (2010) Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol 21:2069–2080
67. Komers R, Mar D, Denisenko O, Xu B, Oyama TT, Bomsztyk K (2013) Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes. Lab Investig J Tech Methods Pathol 93:543–552
68. Bock F, Shahzad K, Wang H et al (2013) Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc. Proc Natl Acad Sci U S A 110:648–653
69. Chen J, Guo Y, Zeng W et al (2014) ER stress triggers MCP-1 expression through SET7/9-induced histone methylation in the kidneys of db/db mice. Am J Physiol Ren Physiol 306:F916–F925
70. Reddy MA, Sumanth P, Lanting L et al (2014) Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int 85:362–373
71. Ruggenenti P, Cravedi P, Remuzzi G (2010) The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol 6:319–330
72. Perrone L, Devi TS, Hosoya K, Terasaki T, Singh LP (2009) Thioredoxin interacting protein (TXNIP) induces inflammation through chromatin modification in retinal capillary endothelial cells under diabetic conditions. J Cell Physiol 221:262–272
73. Kadiyala CS, Zheng L, Du Y et al (2012) Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J Biol Chem 287:25869–25880
74. Kaur H, Chen S, Xin X, Chiu J, Khan ZA, Chakrabarti S (2006) Diabetes-induced extracellular matrix protein expression is mediated by transcription coactivator p300. Diabetes 55:3104–3111
75. Feng B, Chen S, Chiu J, George B, Chakrabarti S (2008) Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level. Am J Physiol Endocrinol Metab 294:E1119–E1126
76. Rafehi H, El-Osta A, Karagiannis TC (2011) Genetic and epigenetic events in diabetic wound healing. Int Wound J 8:12–21
77. Miao F, Gonzalo IG, Lanting L, Natarajan R (2004) In vivo chromatin remodeling events leading to inflammatory gene transcription under diabetic conditions. J Biol Chem 279:18091–18097
78. Miao F, Wu X, Zhang L, Yuan YC, Riggs AD, Natarajan R (2007) Genome-wide analysis of histone lysine methylation variations caused by diabetic conditions in human monocytes. J Biol Chem 282:13854–13863
79. Miao F, Smith DD, Zhang L, Min A, Feng W, Natarajan R (2008) Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes. Diabetes 57:3189–3198
80. Miao F, Chen Z, Zhang L et al (2012) Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes. J Biol Chem 287:16335–16345
81. Li Y, Reddy MA, Miao F et al (2008) Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-κB-dependent inflammatory genes. Relevance to diabetes and inflammation. J Biol Chem 283:26771–26781
82. Okabe J, Orlowski C, Balcerczyk A et al (2012) Distinguishing hyperglycaemic changes by Set7 in vascular endothelial cells. Circ Res 110:1067–1076
83. Okabe J, Fernandez AZ, Ziemann M, Keating ST, Balcerczyk A, El-Osta A (2014) Endothelial transcriptome in response to pharmacological methyltransferase inhibition. ChemMedChem 9:1755–1762
84. Villeneuve LM, Kato M, Reddy MA, Wang M, Lanting L, Natarajan R (2010) Enhanced levels of microRNA-125b in vascular smooth muscle cells of diabetic db/db mice lead to increased inflammatory gene expression by targeting the histone methyltransferase Suv39h1. Diabetes 59:2904–2915
85. Miao F, Chen Z, Genuth S et al (2014) Evaluating the role of epigenetic histone modifications in the metabolic memory of type 1 diabetes. Diabetes 63:1748–1762
86. Guttman M, Amit I, Garber M et al (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458:223–227
87. Alvarez ML, Distefano JK (2013) The role of non-coding RNAs in diabetic nephropathy: potential applications as biomarkers for disease development and progression. Diabetes Res Clin Pract 99:1–11
88. Kato M, Castro NE, Natarajan R (2013) MicroRNAs: potential mediators and biomarkers of diabetic complications. Free Radic Biol Med 64:85–94
89. Kantharidis P, Wang B, Carew RM, Lan HY (2011) Diabetes complications: the microRNA perspective. Diabetes 60:1832–1837
90. Badal SS, Danesh FR (2014) MicroRNAs and their applications in kidney diseases. Pediatr Nephrol. doi:10.1007/s00467-014-2867-7
91. Zhou Q, Lv D, Chen P et al (2014) MicroRNAs in diabetic cardiomyopathy and clinical perspectives. Front Genet 5:185
92. Cabili MN, Trapnell C, Goff L et al (2011) Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses. Genes Dev 25:1915–1927
93. Kato M, Putta S, Wang M et al (2009) TGF-β activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11:881–889
94. Alvarez ML, DiStefano JK (2011) Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy. PLoS One 6:e18671
95. Hanson RL, Craig DW, Millis MP et al (2007) Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 56:975–983
96. Leung A, Trac C, Jin W et al (2013) Novel long noncoding RNAs Are regulated by angiotensin II in vascular smooth muscle cells. Circ Res 113:266–278
97. Reddy MA, Chen Z, Park JT et al (2014) Regulation of inflammatory phenotype in macrophages by a diabetes-induced long non-coding RNA. Diabetes. doi:10.2337/db14-0298
98. Mali P, Aach J, Stranges PB et al (2013) CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 31:833–838
99. Hawkins RD, Hon GC, Ren B (2010) Next-generation genomics: an integrative approach. Nat Rev Genet 11:476–486
100. Laird PW (2010) Principles and challenges of genome-wide DNA methylation analysis. Nat Rev Genet 11:191–203
101. Simon JM, Giresi PG, Davis IJ, Lieb JD (2012) Using formaldehyde-assisted isolation of regulatory elements (FAIRE) to isolate active regulatory DNA. Nat Protoc 7:256–267
102. Leung A, Parks BW, Du J et al (2014) Open chromatin profiling in mice livers reveals unique chromatin variations induced by high fat diet. J Biol Chem 289:23557–23567
103. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B (2008) Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 5:621–628
104. Mouse ENCODE Consortium, Stamatoyannopoulos JA, Snyder M et al (2012) An encyclopedia of mouse DNA elements (Mouse ENCODE). Genome Biol 13:418
105. Hodgin JB, Nair V, Zhang H et al (2013) Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 62:299–308
106. Ronn T, Ling C (2013) Effect of exercise on DNA methylation and metabolism in human adipose tissue and skeletal muscle. Epigenomics 5:603–605